Davern Capital Partners, LP — 13F Holdings & Portfolio
CIK 2003147 · latest 13F-HR filed 2026-08-13
Davern Capital Partners, LP manages $586.5M in 13F-reported U.S. long-equity assets across 15 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are BNTX (11.97%), ROIV (11.66%), RPRX (11.05%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 5; 12 existing positions rose in reported value and 0 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 86.8%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 27, 2026.
2ND FLOOR
NEW YORK, NY 10022
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CHALKDUST TORTURE LLC Control | LIMITED PARTNER since May 2022 | 75% or more | Domestic Entity |
| DAVERN CAPITAL PARTNERS MANAGEMENT COMPANY GP, LLC Control | GENERAL PARTNER since May 2022 | Less than 5% | Domestic Entity |
| KOBRIN, ELIE Control | FOUNDER AND CHIEF INVESTMENT OFFICER since May 2022 | Less than 5% | Individual |
| SCHANKLER, SUSANNA, BETH Control | PRESIDENT AND PARTNER | CHIEF COMPLIANCE OFFICER since Dec 2022 | Less than 5% | Individual |
| BETH MOUNTAIN LLC | LIMITED PARTNER since Dec 2022 | 5–10% | Domestic Entity |
| KOBRIN, ELIE Control Indirect owner via DAVERN CAPITAL PARTNERS MANAGEMENT COMPANY GP, LLC | MANAGING MEMBER since May 2022 | 75% or more | Individual |
| KOBRIN, ELIE Indirect owner via CHALKDUST TORTURE LLC | MANAGING MEMBER since May 2022 | 75% or more | Individual |
| SCHANKLER, SUSANNA, BETH Indirect owner via BETH MOUNTAIN LLC | MANAGING MEMBER since Dec 2022 | 75% or more | Individual |
Ownership & leadership changes · 1 filing with changes since Jan 27, 2023
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedBETH MOUNTAIN LLC · LIMITED PARTNER · 5–10%
- AddedCHALKDUST TORTURE LLC · LIMITED PARTNER · 75% or more · control person
- AddedKOBRIN, ELIE · MANAGING MEMBER · 75% or more · indirect via CHALKDUST TORTURE LLC
- AddedSCHANKLER, SUSANNA, BETH · MANAGING MEMBER · 75% or more · indirect via BETH MOUNTAIN LLC
- ChangedKOBRIN, ELIE · title FOUNDER AND CHIEF INVESTMENT OFFICER | LIMITED PARTNER → FOUNDER AND CHIEF INVESTMENT OFFICER; ownership 75% or more → Less than 5%
- ChangedSCHANKLER, SUSANNA, BETH · title PRESIDENT AND PARTNER | CHIEF COMPLIANCE OFFICER | LIMITED PARTNER → PRESIDENT AND PARTNER | CHIEF COMPLIANCE OFFICER; ownership 5–10% → Less than 5%
- ListedDAVERN CAPITAL PARTNERS MANAGEMENT COMPANY GP, LLC · GENERAL PARTNER · Less than 5% · control person
- ListedKOBRIN, ELIE · FOUNDER AND CHIEF INVESTMENT OFFICER | LIMITED PARTNER · 75% or more · control person
- ListedKOBRIN, ELIE · MANAGING MEMBER · 75% or more · indirect via DAVERN CAPITAL PARTNERS MANAGEMENT COMPANY GP, LLC · control person
- ListedSCHANKLER, SUSANNA, BETH · PRESIDENT AND PARTNER | CHIEF COMPLIANCE OFFICER | LIMITED PARTNER · 5–10% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ROIVANT SCIENCES LTD$44.2M +182.7%
- BIONTECH SE$43.1M +159.0%
- ROYALTY PHARMA PLC$39.9M +159.8%
- IONIS PHARMACEUTICALS INC$34.3M +118.0%
- INSMED INC$29.8M +99.9%
New Positions
Show all 3 →Exited Positions
- PFIZER INC$44.8M
- ARGENX SE$25.6M
- ELI LILLY & CO$25.1M
- ABIVAX SA$8.7M
- VIRIDIAN THERAPEUTICS INC$5.9M
Davern Capital Partners, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BIONTECH SE | BNTX | 09075V102 | $70.2M | 11.97% | 754,550 | SH |
| 2 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $68.4M | 11.66% | 1,932,904 | SH |
| 3 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $64.8M | 11.05% | 1,155,809 | SH |
| 4 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $63.3M | 10.80% | 798,709 | SH |
| 5 | INSMED INC | INSM | 457669307 | $59.7M | 10.18% | 559,824 | SH |
| 6 | REGENERON PHARMACEUTICALS | REGN | 75886F107 | $57.8M | 9.85% | 92,640 | SH |
| 7 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $34.4M | 5.87% | 1,191,522 | SH |
| 8 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $34.0M | 5.80% | 113,085 | SH |
| 9 | NATERA INC | NTRA | 632307104 | $32.3M | 5.51% | 118,975 | SH |
| 10 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $23.9M | 4.08% | 446,059 | SH |
| 11 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $23.2M | 3.95% | 858,753 | SH |
| 12 | VERA THERAPEUTICS INC | VERA | 92337R101 | $21.4M | 3.65% | 498,832 | SH |
| 13 | GENERATE BIOMEDICINES INC | GENB | 370920100 | $13.9M | 2.37% | 824,679 | SH |
| 14 | PROCEPT BIOROBOTICS CORP | PRCT | 74276L105 | $10.5M | 1.79% | 464,920 | SH |
| 15 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $8.7M | 1.48% | 468,666 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $586.5M | 15 | 0000905148-26-003614 |
| 2026-03-31 | 2026-05-14 | $364.5M | 17 | 0000905148-26-002267 |
| 2025-12-31 | 2026-02-13 | $309.3M | 14 | 0000905148-26-000704 |
2ND FLOOR
NY, NY 10022